Stockscreener 앱 받기
10.46
3.86%
-0.42
시간 외 거래:
10.44
-0.02
-0.19%
전일 마감가:
$10.88
열려 있는:
$10.85
하루 거래량:
855.06K
Relative Volume:
0.74
시가총액:
$566.77M
수익:
$1.02B
순이익/손실:
$-757.20M
주가수익비율:
-0.7087
EPS:
-14.76
순현금흐름:
$-257.90M
1주 성능:
-5.85%
1개월 성능:
+1.85%
6개월 성능:
+6.09%
1년 성능:
+570.51%
1일 변동 폭
$10.36
$11.00
1주일 범위
$10.12
$11.75
52주 변동 폭
$1.47
$15.10
Emergent Biosolutions Inc Stock (EBS) Company Profile
명칭
Emergent Biosolutions Inc
전화
240-631-3200
주소
300 PROFESSIONAL DR, GAITHERSBURG, MD
EBS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
10.46 | 566.77M | 1.02B | -757.20M | -257.90M | -14.76 |
|
ZTS
Zoetis Inc
|
174.12 | 78.56B | 9.15B | 2.43B | 2.31B | 5.32 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.61 | 43.15B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
9.51 | 43.00B | 14.26B | 1.55B | 0 | 0.3383 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.29 | 19.59B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
150.51 | 15.24B | 2.24B | 385.90M | 440.10M | 3.73 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-22 | 개시 | Rodman & Renshaw | Buy |
| 2024-03-07 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-11-20 | 재개 | JP Morgan | Underweight |
| 2023-08-29 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-04-10 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-03-17 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-11-10 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2022-04-29 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2022-01-20 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-11-08 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-05-05 | 다운그레이드 | Argus | Buy → Hold |
| 2021-04-07 | 개시 | The Benchmark Company | Buy |
| 2021-02-24 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2021-02-19 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2021-01-08 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-09-14 | 재개 | JP Morgan | Neutral |
| 2020-07-31 | 재확인 | Chardan Capital Markets | Buy |
| 2019-09-12 | 개시 | Guggenheim | Buy |
| 2019-09-04 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2018-11-02 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-08-03 | 재확인 | Chardan Capital Markets | Buy |
| 2018-06-13 | 개시 | Argus | Buy |
| 2018-04-25 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2018-01-16 | 재확인 | Chardan Capital Markets | Buy |
| 2016-06-28 | 재확인 | Singular Research | Buy |
| 2016-04-15 | 개시 | Chardan Capital Markets | Buy |
| 2016-03-28 | 개시 | Singular Research | Buy |
| 2016-02-19 | 개시 | Wells Fargo | Outperform |
| 2014-05-15 | 개시 | Summer Street Research | Buy |
| 2011-05-31 | 재확인 | WBB Securities | Strong Buy |
| 2011-01-10 | 재확인 | Wedbush | Outperform |
| 2010-11-05 | 재확인 | Wedbush | Outperform |
| 2010-08-18 | 업그레이드 | WBB Securities | Buy → Strong Buy |
| 2010-08-06 | 재확인 | Caris & Company | Buy |
모두보기
Emergent Biosolutions Inc 주식(EBS)의 최신 뉴스
Emergent BioSolutions (NYSE:EBS) Trading Down 7%Here's Why - MarketBeat
Emergent BioSolutions (NYSE:EBS) Shares Down 3.9%What's Next? - MarketBeat
Where are the Opportunities in (EBS) - Stock Traders Daily
Emergent BioSolutions up 10% on HC Wainwright buy initiation - MSN
Emergent BioSolutions’ CEO Sold $11 Million worth of stock before error in Baltimore went public - WBAL Radio
Emergent BioSolutions Inc. to Host Earnings Call - ACCESS Newswire
Emergent BioSolutions (NYSE:EBS) Stock Rating Lowered by StockNews.com - MarketBeat
Emergent BioSolutions Inc (EBS) Stock Price Up 3.4% on Jan 24 - GuruFocus.com
Emergent BioSolutions (NYSE:EBS) Trading 7.2% HigherTime to Buy? - MarketBeat
Emergent seeking to reverse fortunes and become a major overdose treatment player - Pharmaceutical Technology
There's No Escaping Emergent BioSolutions Inc.'s (NYSE:EBS) Muted Revenues Despite A 26% Share Price Rise - Simply Wall St
Emergent BioSolutions stock reaffirms buy rating on contract modification - MSN
Emergent BioSolutions (NYSE:EBS) Earns "Buy" Rating from HC Wainwright - MarketBeat
Emergent BioSolutions stock reaffirms buy rating on contract modification By Investing.com - Investing.com UK
The Analyst Verdict: Emergent BioSolutions In The Eyes Of 4 Experts - Benzinga
EBS (Emergent BioSolutions) Revenue : $1,094 Mil (TTM As of Sep. 2024) - GuruFocus.com
Blood Plasma Market Growing at 4.07% CAGR to Hit 42.0 Billion USD by 2032 | Emergent BioSolutions, ADMA - EIN News
Barclays PLC Has $329,000 Stake in Emergent BioSolutions Inc. (NYSE:EBS) - MarketBeat
EBS (Emergent BioSolutions) Free Cash Flow : $138 Mil (TTM As of Sep. 2024) - GuruFocus.com
Emergent BioSolutions gains exclusive commercial rights to KLOXXADO - MSN
Africa CDC Launches Groundbreaking Pan-African Mpox Treatment Trial in DRC - StockTitan
Emergent BioSolutions presents at healthcare conference By Investing.com - Investing.com Australia
Emergent BioSolutions Outlines Growth at J.P. Morgan Conference - TipRanks
Emergent BioSolutions presents at healthcare conference - Investing.com
Rep. Steve Cohen Sells Emergent BioSolutions Inc. (NYSE:EBS) Stock - MarketBeat
StockNews.com Upgrades Emergent BioSolutions (NYSE:EBS) to Buy - MarketBeat
Emergent secures rights to KLOXXADO nasal spray By Investing.com - Investing.com Canada
Hikma announces exclusive commercial partnership with Emergent BioSolutions for KLOXXADO® (naloxone HCl) nasal spray 8 mg - The Malaysian Reserve
Hikma announces exclusive commercial partnership with Emergent B - GuruFocus.com
Emergent secures rights to KLOXXADO nasal spray - Investing.com
Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals - The Manila Times
Emergent BioSolutions: Stock Is A Likely Winner In 2025 (NYSE:EBS) - Seeking Alpha
Hikma Partners with Emergent BioSolutions for KLOXXADO® Opioid Overdose Treatment Distribution - StockTitan
Emergent BioSolutions Expands Overdose Treatment Portfolio with Exclusive KLOXXADO Rights - StockTitan
Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola - The Manila Times
Emergent BioSolutions Secures $16.7M BARDA Contract for Ebola Treatment Development - StockTitan
Emergent BioSolutions exercises $20M option to supply DoD with BioThrax - MSN
HC Wainwright Reiterates Buy Rating for Emergent BioSolutions (NYSE:EBS) - MarketBeat
Those who invested in Emergent BioSolutions (NYSE:EBS) a year ago are up 365% - Yahoo Finance
Emergent BioSolutions Receives $20 Million Contract to Supply Anthrax Vaccine to US Military - Marketscreener.com
Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed) - The Manila Times
Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 - Marketscreener.com
Emergent BioSolutions Secures $20M Defense Contract for Anthrax Vaccine BioThrax - StockTitan
Emergent Stock Skyrockets 251% YTD: How to Play the Stock? - MSN
The 13% return this week takes Emergent BioSolutions' (NYSE:EBS) shareholders one-year gains to 285% - Simply Wall St
HC Wainwright & Co. Initiates Coverage of Emergent BioSolutions (EBS) with Buy Recommendation - MSN
Emergent Biosolutions Inc (EBS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.25%
0.51%
자본화:
|
볼륨(24시간):